Case Report: rapid clinical complete response to Iparomlimab and Tuvonralimab combined with radiotherapy and chemotherapy in a patient with MSS/pMMR locally advanced rectal cancer
Jue Wang, Tao Yang, Jingrui Zhou, Weimin Chen, Guiwei Wang, Chaoyu Mei, Ziwei Chen, Jibiao Li, Tao Shen · 2026
Read Case Report: rapid clinical complete response to Iparomlimab and Tuvonralimab combined with radiotherapy and chemotherapy in a patient with MSS/pMMR locally advanced rectal cancer by Jue Wang, Tao Yang, Jingrui Zhou, Weimin Chen, Guiwei Wang, Chaoyu Mei, Ziwei Chen, Jibiao Li, Tao Shen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619410.txt.
Description
Jue Wang and co-authors report, in a 2026 case paper, a fast full response in a hard form of rectal cancer. The man, 61, had stage IIIB disease of a kind that most times shrugs off immune drugs: stable satellites and sound repair genes. Care mixed a dual immune drug, which hits PD-1 and CTLA-4 at once, with the XELOX drug pair and rays at 45 gray in 25 hits. Check paths were touch exams, scans, scope views, and tissue bits. Scans at week 12 first showed a full clear. Scope and tissue proof at week 20 backed the call.
No grave immune ill came. At the last check, in March 2026, no return had shown. The team casts the mix as a path to spare the organ.
Catalog record
| CREATOR | Jue Wang, Tao Yang, Jingrui Zhou, Weimin Chen, Guiwei Wang, Chaoyu Mei, Ziwei Chen, Jibiao Li, Tao Shen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |